as someone who has done extensive DD on this company and the market, I can't even waste my time with an ignorant and arrogant comment like yours. You deserve my ignore. Your earned it so fast.
My take is that the Discover Growth Fund is helping Tilson/shorts cover by using shark like methods. The notice they gave to UNIS on 11/13 for 50 shares to convert was probably not received by UNIS, then the Unfriendly investor Discover Fund followed up with 11/19 notice for 200 MORE shares as well as declaring a trigger event because they were not timely issued shares from the first notice. These 7.2M shares will most certainly be used by shorts to cover positions in the likelihood of a strategic partnership by paying Discover Growth Fund with a dark pool transaction at an agreed upon price less than $2. I never felt right about this Fund as they are based in the Cayman Islands with no disclosures and it was initiated in 2014 with no real history to draw upon. In the end, I feel the shorts are doing whatever they can to cover ahead of commercialization and this is one of the ways. Now, let's hope that Sanofi, Abbvie, MedImmune and other strategic partners are not going to hit UNIS below the belt like this one.
Typingatu, you seem to have a very negative opinion just as the Malone factor kicked in. Where were you when LGF was languishing for a whole year between $25 and $30. Then I think you would have been more effective and believable. Now that there is interest from big media players you are all gloom and doom on the Lion's prospects. Too funny. You crack me up.
It has been a long while since we had short rantings on this board. In the end, it means we ultimately go up. Last time they were here was during and after HG1 as it took 3 quarters for the significant cash flow to show in the numbers.
Typingatu, the loss on Witchhunter was less than $15M, Jon made that clear in the CC. Their rule of thumb is to average $13M exposure on each film. This is extraordinary control that has not changed even with these big budget films.
Ind1jo, IMO Unilife does not sacrifice margins or scale by being more customized. It is just more time upfront in designing the right product for the right drug. When building something relevant for the next 20 years, you can't just sprint to the finish line, you have to building something that will endure for all the marathons ahead. Unilife has a model from ground up whereas legacy companies (ie West in business for 90 years) build more within existing parameters. We don't have a crystal ball to see the future, but we will see by 2020 if our approach keeps scoring homeruns with new drugs being offered in our devices for a LONG time.
typingatu....all the pessimism....For what its worth, even box office flops like Mordecai have a library value that keeps on giving. Many will want to watch it on demand. I actually like the movie very much and am disappointed that it will not have any sequels. It was quirky and fun....just not the type of flick that is "in" at the moment, but many will appreciate it outside of the box office nonetheless. This will be the case for all the movies that do not do well in boxoffice so why are you so focused on a metric that no longer defines success of a business? Lionsgate keeps producing content for ALL GENRES and audiences (both domestic and GLOBAL) with minimal risk and in the process keeps building its valuable library that will keep giving for years to come.
Michaelhunt, what do you you mean keep wishing? Sanofi signed exclusive contract for Lovenox PFS, there is nothing to wish for, it is already done and will be commercialized. FACT not wish.
Ind1jo, I have been informed by an experienced medical device source that the West Smartdose device is not as customized as Unilife. Unilife devices are made to fit the Client's requirements, where West is more like legacy offerings in the sense that the Pharma needs to conform to the specs of the device. Surely, West has customers as they are already a leader in the device industry and Pharma trusts them. I would also think that not all Pharma need customized solutions for their drugs. My understanding is that Unilife's device is most modular than any device on the market in that each component is separate and can be customized in the building out of the complete device.
ind21jo, thanks for your additional comments of substance on Nuelasta. I don't disagree with you on any of the points you made. I certainly think that the Omnipod is appropriate at this time as the best option to treat cancer patients most effectively as there aren't any alternatives on the market at this time. If you listen to Insulet's conference calls, they indicate that there is no new platform for biologics as it will all stem from adjustments to the Omnipod Diabetes technology and will only be modified with respect to dosing and administration requirements for specific drugs. However, they do intend to increase spending to $50M on R&D that will include not only improvements to the Omnipod, but expansion into biologics. My point is, they are behind and playing catch up. There are the best available option out there right now, but I don't think it will last if Unilife's WI is as great as Sanofi, MedImmune, etc think it is as they are locked into using it for 15 years. Also, if UNIS's WI becomes the model leader, then competitors will try to perfect it even more. IMO we will be first to market as the disruptive leader in wearable injectors. But another horse can surely come riding in. I am on the look out.
I learned that Unilife is secure in its patents. The patents are further vetted by Big Pharma before they enter into long term contracts. Based on that, you can be assured that Sanofi and MedImmune both validated the intellectual property of the device platforms. Although others may develop around Unilfe's technology for similar type devices, I believe that there is a firm advantage to being first that keeps you in the lead. The fact that Unilife has already secured the ONLY 2 long term WI contracts as well as long term PFS contracts with multiple customers in the industry speaks volumes.
I learned that West Pharma's platform is not as customized as Unilfe devices. I also learned that although they are indicating that demand for their wearable injectors is growing, they do not yet have 1 signed long term agreement. Unilife is certainly in the lead as they have 2 signed agreements for 15 years with Sanofi and MedImmune.
If anyone has ever been involved in a multiple bid process on the home of your dreams, you know you will bid at asking price or at a premium to ensure that you have a good chance to win your prize. The same process is underway here.
I can assure you from the opinions for reputable sources that Unilife will not go bankrupt. Also, MS is doing a very professional and thorough job valuing the company based on current contracts, assets/IP, and a vetted valuation of current negotiations with potential customers without regard to the current market cap. The Short scammers are the ones preventing capital raising by choking the stock price. Hastings is doing an incredible job in his power to source financing without diluting the company at this ridiculous level. Orbimed has been more than supportive in that endeavor as well. Now Teach, give me some more substance instead of your short thesis ramblings.
Update: I recently learned that Insulet supplies Amgen with a patch pump for Nuelasta that is NOT patient administered. The patient goes in for an office visit where the Doctor assembles the device and attaches it to the patient. This certainly does not compete with the ease and comfort of patient use of Unilife wearable injectors IMO. Insulet is making $30M/annual run rate for this inferior product (for one cancer drug), I believe the opportunities are greater for Unilife devices.
Remarks from Keith Markey, Griffin Securities
After the formal meeting ended, we spoke with management.
Here are a few takeaways and impressions:
■ Production equipment is being installed on schedule.
Besides the original Unifill™ production line, the Company now
as a Finesse™ syringe line in place and will be completing
installation of a Nexus™ syringe line next week. In addition,
a second Finesse line will be installed in the March quarter.
Our impression is that the two Finesse lines, which produce
syringes for Sanofi, indicate the customer that accelerated its
orders recently is the French drug manufacturer.
■ The AbbVie supply agreement seems close to being
signed. A key perquisite to cementing the relationship has
been a shipment of Lisa™ autoinjectors to AbbVie. Since Unilife
will be shipping them in the very near future, we think the
commercial supply agreement will be inked soon, perhaps
before year end.
■ A strategic financing will probably be completed before
December 31st. Numerous interested parties have been
given access to a data room in which Unilife has placed
more than 1,000 documents, and several bids have already
been received by Morgan Stanley. The potential sources of
capital include suppliers/vendors to Unilife, pharmaceutical
companies, competitors, and private investors. Our impression
is that the financing will be completed by year end since more
than one bid has been received. The unknown, of course, is the
■ Ongoing discussions with pharmaceutical companies are
real. Unlike announcements in the past that didn’t always yield
new business in the subsequent months, the 12 or so that were
referenced at the meeting were evaluated internally and vetted
by outside counsel to support the strategic financing initiative.
Our impression is that the short list is an honest assessment of
new, potentially near-term business.
MS is doing a very good job with the review. They are valuing the company without regard to the current price it is trading at. Bankruptcy is unlikely. JPM is continuing to buy on the premise that Unilife is a viable company going forward into its commercialization phase. Believe it or not, it is your choice.
Obviously, this last item was important to investors to take note as Hastings made a conscious effort to emphasize the support of Orbimed in waiving revenue requirements and not changing any terms of the loan; royalties or interest rates. This is a big tell that we are not headed for bankruptcy as some will try to lead us to believe on this board.